Press "Enter" to skip to content

More Breast-Implant Lymphoma; Assisted Reproduction and Cancer; Chocolate News

The number of cases of breast implant-associated anaplastic large-cell lymphoma increased to 457, according to the FDA.

An artificial intelligence-derived prediction model achieved the best accuracy yet for distinguishing between high- and low-risk prostate cancer. (Scientific Reports)

Immune checkpoint inhibitors appeared to be safe and effective for patients with cancer and HIV infection. (Georgetown Lombardi Comprehensive Cancer Center, JAMA Oncology)

The U.S. Preventive Services Task Force continued to recommend against screening for pancreatic cancer in asymptomatic adults.

Efforts to reduce lung cancer mortality paid off in England with an estimated 500,000 fewer deaths than would have been projected in 1979 from then-current trends. (Cancer Research UK)

The CAR T-cell therapy tisagenlecleucel (Kymriah) passed muster with England’s cost-effectiveness agency, which recommended the therapy for adults with relapsed/refractory diffuse large B-cell lymphoma. (NICE)

A study of children and young adults conceived by assisted reproduction showed no increased risk of cancer. (The Netherlands Cancer Institute, Human Reproduction)

Rates of obesity-related cancers increased among young adults, with a trend toward cancer onset at younger ages. (The Lancet Public Health)

A silver lining for chocolate lovers: The health-related news isn’t all bad. (American Cancer Society)

More evidence that stereotactic radiotherapy may help improve survival in stage IV lung cancer. (University of Pittsburgh, ASTRO)

The adverse effects of cancer therapy on bones needs more attention, recognition, research, and preventive strategies. (British Journal of Clinical Pharmacology)

MacroGenics said its investigational agent margetuximab improved progression-free survival compared with trastuzumab (Herceptin) in a phase III trial involving patients with metastatic HER2-positive breast cancer.

NoxoPharm announced favorable results from a preliminary trial of its radiotherapy-enhancing agent idronoxil (Veyonda) in prostate cancer.